Screening and treatment progression of elderly cervical cancer

doi:10.3760/cma.j.cn371439-20220816-00148

Abstract

Abstract:

The prognosis of elderly patients with cervical cancer is poor. Currently, some studies show that elderly women still need regular screening for cervical cancer, and clinical screening methods with higher sensitivity for elderly women need to be explored. In terms of treatment, fewer elderly patients choose surgery, and radiotherapy is the most commonly used treatment. However, there is still no conclusion on whether chemotherapy, targeted therapy and immunological therapy should be added during radiotherapy.

Key words: Uterine cervical neoplasms, Aged, Mass screening, Therapeutics

Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting. Screening and treatment progression of elderly cervical cancer[J]. Journal of International Oncology, 2022, 49(12): 754-758.

References 41

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.0000000000002108. doi: 10.1097/CM9.0000000000002108
[3]	Nishimura H, Yeh PT, Oguntade H, et al. HPV self-sampling for cervical cancer screening: a systematic review of values and preferences[J]. BMJ Glob Health, 2021, 6(5): e003743. DOI: 10.1136/bmjgh-2020-003743. doi: 10.1136/bmjgh-2020-003743
[4]	Huang J, Deng Y, Boakye D, et al. Global distribution, risk factors, and recent trends for cervical cancer: a worldwide country-level analysis[J]. Gynecol Oncol, 2022, 164(1): 85-92. DOI: 10.1016/j.ygyno.2021.11.005. doi: 10.1016/j.ygyno.2021.11.005
[5]	Wenzel HHB, Bekkers RLM, Lemmens VEPP, et al. No improve-ment in survival of older women with cervical cancer—a nationwide study[J]. Eur J Cancer, 2021, 151: 159-167. DOI: 10.1016/j.ejca.2021.04.014. doi: 10.1016/j.ejca.2021.04.014 pmid: 33993062
[6]	Hammer A, Soegaard V, Maimburg RD, et al. Cervical cancer screening history prior to a diagnosis of cervical cancer in Danish women aged 60 years and older—a national cohort study[J]. Cancer Med, 2019, 8(1): 418-427. DOI: 10.1002/cam4.1926. doi: 10.1002/cam4.1926
[7]	Gustafson LW, Petersen LK, Bor P, et al. Cervical cancer prevention among older women-challenges in screening, diagnostic workup and treatment[J]. Acta Obstet Gynecol Scand, 2021, 100(8): 1364-1368. DOI: 10.1111/aogs.14162. doi: 10.1111/aogs.14162
[8]	宋明泽, 程一鸣, 李刚, 等. P16/Ki-67双染检测技术在宫颈癌及癌前病变筛查中的价值[J]. 国际肿瘤学杂志, 2020, 47(11): 675-681. DOI: 10.3760/cma.j.cn371439-20191224-00099. doi: 10.3760/cma.j.cn371439-20191224-00099
[9]	Dilley S, Huh W, Blechter B, et al. It's time to re-evaluate cervical cancer screening after age 65[J]. Gynecol Oncol, 2021, 162(1): 200-202. DOI: 10.1016/j.ygyno.2021.04.027. doi: 10.1016/j.ygyno.2021.04.027 pmid: 33926748
[10]	Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors[J]. J Low Genit Tract Dis, 2020, 24(2): 102-131. DOI: 10.1097/LGT.0000000000000525. doi: 10.1097/LGT.0000000000000525
[11]	孙萍, 徐志坚, 张凯, 等. 65岁及以上老年女性宫颈癌机会性筛查的价值[J]. 中华健康管理学杂志, 2019, 13(5): 411-415. DOI: 10.3760/cma.j.issn.1674-0815.2019.05.007. doi: 10.3760/cma.j.issn.1674-0815.2019.05.007
[12]	Nogueira-Rodrigues A, de Melo AC, Garces AH, et al. Patterns of care and outcome of elderly women diagnosed with cervical cancer in the developing world[J]. Int J Gynecol Cancer, 2016, 26(7): 1246-1251. DOI: 10.1097/IGC.0000000000000756. doi: 10.1097/IGC.0000000000000756 pmid: 27465885
[13]	Nosaka K, Shibata K, Utsumi F, et al. Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer[J]. Tumori, 2016, 102(6): 600-605. DOI: 10.5301/tj.5000530. doi: 10.5301/tj.5000530 pmid: 27443893
[14]	Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer[J]. N Engl J Med, 2018, 379(20): 1895-1904. DOI: 10.1056/NEJMoa1806395. doi: 10.1056/NEJMoa1806395
[15]	Luo C, Liu M, Li X. Efficacy and safety outcomes of robotic radical hysterectomy in Chinese older women with cervical cancer com-pared with laparoscopic radical hysterectomy[J]. BMC Womens Health, 2018, 18(1): 61. DOI: 10.1186/s12905-018-0544-x. doi: 10.1186/s12905-018-0544-x
[16]	中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 474-489. DOI: 10.19401/j.cnki.1007-3639.2021.06.06. doi: 10.19401/j.cnki.1007-3639.2021.06.06
[17]	Hata M. Radiation therapy for elderly patients with uterine cervical cancer: feasibility of curative treatment[J]. Int J Gynecol Cancer, 2019, 29(3): 622-629. DOI: 10.1136/ijgc-2018-000077. doi: 10.1136/ijgc-2018-000077 pmid: 30630886
[18]	Hou P, Hsieh C, Wei M, et al. Differences in treatment outcomes and prognosis between elderly and younger patients receiving definitive radiotherapy for cervical cancer[J]. Int J Environ Res Public Health, 2020, 17(12): 4510. DOI: 10.3390/ijerph17124510. doi: 10.3390/ijerph17124510
[19]	Nakamura R, Shimoji Y, Nakasone T, et al. Relative dose inten-sity and overall treatment time in older patients with cervical cancer treated with concurrent chemoradiotherapy[J]. J Geriatr Oncol, 2021, 12(2): 332-334. DOI: 10.1016/j.jgo.2020.09.007. doi: 10.1016/j.jgo.2020.09.007 pmid: 32938543
[20]	Chopra S, Gupta S, Kannan S, et al. Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer (PARCER): a randomized con-trolled trial[J]. J Clin Oncol, 2021, 39(33): 3682-3692. DOI: 10.1200/JCO.20.02530. doi: 10.1200/JCO.20.02530
[21]	Rodrigues MJ, Zapardiel I, Frélaut M, et al. A call for specific geriatric data on cervical cancers[J]. Future Oncol, 2016, 12(9): 1101-1104. DOI: 10.2217/fon-2016-0022. doi: 10.2217/fon-2016-0022 pmid: 26955977
[22]	Trifanescu OG, Gales LN, Serbanescu GL, et al. Long-term onco-logical outcome in patients with cervical cancer after 3 trimodality treatment (radiotherapy, platinum-based chemotherapy, and robotic surgery)[J]. Medicine (Baltimore), 2021, 100(13): e25271. DOI: 10.1097/MD.0000000000025271. doi: 10.1097/MD.0000000000025271
[23]	卢家希, 陈晓品. 紫杉醇联合卡铂化疗同期调强适形放疗对老年晚期宫颈癌患者疗效观察及对患者生活质量和免疫功能影响[J]. 重庆医科大学学报, 2018, 43(2): 240-244. DOI: 10.13406/j.cnki.cyxb.001517. doi: 10.13406/j.cnki.cyxb.001517
[24]	Wang YM, Wang CJ, Fang FM, et al. Differences in the outcomes and complications between elderly and younger uterine cervical cancer patients treated by definitive radiotherapy-a propensity score-matched study[J]. Gynecol Oncol, 2017, 145(2): 277-283. DOI: 10.1016/j.ygyno.2017.02.034. doi: 10.1016/j.ygyno.2017.02.034
[25]	Wang W, Hou X, Yan J, et al. Outcome and toxicity of radical radiotherapy or concurrent chemoradiotherapy for elderly cervical cancer women[J]. BMC Cancer, 2017, 17(1): 510. DOI: 10.1186/s12885-017-3503-2. doi: 10.1186/s12885-017-3503-2 pmid: 28764676
[26]	Shimamoto K, Saito T, Kitade S, et al. A study of treatments and outcomes in elderly women with cervical cancer[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 228: 174-179. DOI: 10.1016/j.ejogrb.2018.06.032. doi: S0301-2115(18)30319-1 pmid: 29960201
[27]	You KY, Peng HH, Jiang YH, et al. Selective use of concurrent chemotherapy in elderly cervical cancer patients treated with definitive radiotherapy: experience from two institutions[J]. Cancer Manag Res, 2019, 11: 4815-4823. DOI: 10.2147/CMAR.S190025. doi: 10.2147/CMAR.S190025
[28]	Kuno I, Takayanagi D, Asami Y, et al. TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer[J]. Sci Rep, 2021, 11(1): 19261. DOI: 10.1038/s41598-021-98527-2. doi: 10.1038/s41598-021-98527-2 pmid: 34584128
[29]	Redondo A, Colombo N, McCormack M, et al. Primary results from CECILIA, a global single-arm phase Ⅱ study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer[J]. Gynecol Oncol, 2020, 159(1): 142-149. DOI: 10.1016/j.ygyno.2020.07.026. doi: 10.1016/j.ygyno.2020.07.026 pmid: 32763109
[30]	Lu H, Wu Y, Liu X, et al. Endostar, an antiangiogenesis inhi-bitor, combined with chemoradiotherapy for locally advanced cervical cancer[J]. Oncol Res, 2022, 28(9): 929-944. DOI: 10.3727/096504021X16318716607908. doi: 10.3727/096504021X16318716607908
[31]	Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)[J]. Lancet Oncol, 2015, 16(3): 301-311. DOI: 10.1016/S1470-2045(15)70004-5. doi: 10.1016/S1470-2045(15)70004-5
[32]	Liu CH, Kung YH, Chien-Fu Lin J, et al. Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer[J]. J Chin Med Assoc, 2021, 84(12): 1139-1144. DOI: 10.1097/JCMA.0000000000000629. doi: 10.1097/JCMA.0000000000000629
[33]	Vora C, Gupta S. Targeted therapy in cervical cancer[J]. ESMO Open, 2018, 3(Suppl 1): e000462. DOI: 10.1136/esmoopen-2018-000462. doi: 10.1136/esmoopen-2018-000462
[34]	Kahraman S, Erbas UE, Yalcin B. Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer?[J]. Med Oncol, 2022, 39(3): 33. DOI: 10.1007/s12032-021-01623-6. doi: 10.1007/s12032-021-01623-6 pmid: 35059847
[35]	Da Silva DM, Enserro DM, Mayadev JS, et al. Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)[J]. Clin Cancer Res, 2020, 26(21): 5621-5630. DOI: 10.1158/1078-0432.CCR-20-0776. doi: 10.1158/1078-0432.CCR-20-0776
[36]	Garcia-Duran C, Grau F, Villacampa G, et al. ATOMICC trial: a randomized, open-label, phase Ⅱ trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation[J]. Int J Gynecol Cancer, 2022, 32: 1196-1200. DOI: 10.1136/ijgc-2022-003370. doi: 10.1136/ijgc-2022-003370
[37]	Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase Ⅱ trial[J]. J Clin Oncol, 2022, 40(16): 1795-1805. DOI: 10.1200/jco.21.02091. doi: 10.1200/jco.21.02091
[38]	Chen J, Li C, Cao Y, et al. Toripalimab combined with concurrent platinum-based chemoradiotherapy in patients with locally advanced cervical cancer: an open-label, single-arm, phase Ⅱ trial[J]. BMC Cancer, 2022, 22(1): 793. DOI: 10.1186/s12885-022-09866-w. doi: 10.1186/s12885-022-09866-w pmid: 35854236
[39]	O'Malley DM, Oaknin A, Monk BJ, et al. Phase Ⅱ study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer[J]. Gynecol Oncol, 2021, 163(2): 274-280. DOI: 10.1016/j.ygyno.2021.08.018. doi: 10.1016/j.ygyno.2021.08.018 pmid: 34452745
[40]	Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persi-stent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385(20): 1856-1867. DOI: 10.1056/NEJMoa2112435. doi: 10.1056/NEJMoa2112435
[41]	郭峰, 陈采枝, 梁叶, 等. 恩度联合化学药物治疗晚期和复发转移性宫颈癌的疗效[J]. 中南大学学报(医学版), 2020, 45(12): 1412-1418. DOI: 10.11817/j.issn.1672-7347.2020.190321. doi: 10.11817/j.issn.1672-7347.2020.190321